Title |
Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence
|
---|---|
Published in |
Current Cardiology Reports, March 2018
|
DOI | 10.1007/s11886-018-0974-y |
Pubmed ID | |
Authors |
Harsha V. Ganga, Abhishek Maan, E. Kevin Heist |
Abstract |
Recent evidence has suggested that implantable defibrillator (ICD) in non-ischemic cardiomyopathy (NICM) may not offer mortality benefit in the presence of guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT). Despite significant benefits of GDMT and CRT, current evidence is derived from ICD trials that rely predominantly on reduced left ventricular ejection fraction alone (LVEF). The majority of patients with sudden cardiac death (SCD) have LVEF > 30% indicating that LVEF by itself is an inadequate predictor of SCD. The Danish study to assess the efficacy of ICD in patients with non-ischemic systolic heart failure on mortality (DANISH) highlights the importance of better risk stratifying NICM patients for ICD implantation. Assessment of life expectancy, comorbidities, presence of advanced heart failure, etiology of NICM, and the presence of myocardial fibrosis can help risk stratify ICD beyond LVEF. Genetics and biomarkers can be of further assistance in risk stratification. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 5 | 19% |
Student > Postgraduate | 4 | 15% |
Student > Ph. D. Student | 3 | 11% |
Student > Doctoral Student | 2 | 7% |
Student > Bachelor | 2 | 7% |
Other | 4 | 15% |
Unknown | 7 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 56% |
Economics, Econometrics and Finance | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Social Sciences | 1 | 4% |
Decision Sciences | 1 | 4% |
Other | 0 | 0% |
Unknown | 8 | 30% |